A Phase I, single-centre, open-label, crossover study in healthy volunteers using scintigraphy to evaluate the gastrointestinal behaviour of EDP2939 oral dosage forms
Latest Information Update: 13 Jun 2023
Price :
$35 *
At a glance
- Drugs EDP 2939 (Primary)
- Indications Inflammation; Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Evelo Biosciences
- 13 Jun 2023 New trial record